PROMOMED became the winner of the Platinum Ounce competition in the "Deal of the Year" nomination

10.04.2025

Corporate
For investors
Industry development

On April 10, Moscow summed up the results of the XXV The Platinum Ounce All–Russian Open Competition for Pharmaceutical Industry Professionals is one of the oldest professional competitions in the Russian pharmaceutical market.

Independent experts and the jury of the competition called the successful holding of the IPO by PROMOMED and the listing of securities on the Moscow Stock Exchange on July 12, 2024 the "Deal of the Year". The placement price is 400 rubles per share, which corresponds to the upper limit of the range. This allowed the Company to raise about 6 billion rubles. The market capitalization of the IPO amounted to 85 billion rubles.

The funds raised were used to bring to the market as soon as possible a wide portfolio of innovative drugs used in endocrinology, oncology, neurology, immunology and other fields of medicine.

PROMOMED Group celebrates its 20th anniversary in 2025. During this time, we have gone from a small company to one of the main players in the national pharmaceutical market. Confidence in the future, passion and dedication to the chosen cause helped to achieve such results. The Company's goal is to provide the healthcare system with modern high–tech drugs for the treatment of socially significant diseases. Eight innovative drugs from the key portfolio are scheduled to be released in 2025. The Platinum Ounce Award in the "Deal of the Year" nomination is a high level of recognition and trust from the pharmaceutical community, which PROMOMED Group has consistently justified for the past 20 years.

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office